Small Extracellular Vesicles as a New Class of Medicines.
Inkyu LeeYoonjeong ChoiDong-U ShinMinjeong KwonSeohyun KimHanul JungGi-Hoon NamMinsu KwonPublished in: Pharmaceutics (2023)
Extracellular vesicles (EVs) are nanovesicles that are naturally released from cells in a lipid bilayer-bound form. A subset population with a size of 200 nm, small EVs (sEVs), is enticing in many ways. Initially perceived as mere waste receptacles, sEVs have revealed other biological functions, such as cell-to-cell signal transduction and communication. Besides their notable biological functions, sEVs have profound advantages as future drug modalities: (i) excellent biocompatibility, (ii) high stability, and (iii) the potential to carry undruggable macromolecules as cargo. Indeed, many biopharmaceutical companies are utilizing sEVs, not only as diagnostic biomarkers but as therapeutic drugs. However, as all inchoate fields are challenging, there are limitations and hindrances in the clinical translation of sEV therapeutics. In this review, we summarize different types of sEV therapeutics, future improvements, and current strategies in large-scale production.
Keyphrases
- single cell
- cell therapy
- induced apoptosis
- small molecule
- current status
- depressive symptoms
- mental health
- heavy metals
- photodynamic therapy
- stem cells
- intellectual disability
- cell cycle arrest
- cell proliferation
- signaling pathway
- mesenchymal stem cells
- endoplasmic reticulum stress
- human health
- drug induced
- bone marrow
- sewage sludge
- municipal solid waste
- life cycle